Roche to present new OCREVUS (ocrelizumab) data in multiple

• OCREVUS data will present important profit on slowing illness exercise and development in sufferers with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS)
• Largest being pregnant security data throughout anti-CD20 medicines for OCREVUS in multiple sclerosis (MS)
• Nine-year security data for OCREVUS reinforces its beneficial benefit-risk profile
• New analysis demonstrates affect of misdiagnosis and delay of beginning remedy in NMOSD

Basel, 19 October 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) at present introduced that new OCREVUS® (ocrelizumab) data and continued analysis into neuromyelitis optica spectrum dysfunction (NMOSD) shall be introduced on the thirty eighth Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 26-28 October 2022. These data embody 35 abstracts, highlighting illness exercise and development outcomes in early-stage RRMS, being pregnant outcomes from greater than 2,000 ladies with MS and long-term security data for OCREVUS, in addition to world NMOSD data exploring affect of delayed remedy, scientific characterization of illness severity and stability, and correct identification of individuals residing with NMOSD via healthcare claims-based algorithms. Finally, the design of a Phase III research evaluating the efficacy and security of satralizumab in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD), a uncommon, persistent and debilitating autoimmune illness primarily affecting the optic nerve, mind and spinal wire, shall be introduced.

“Our aim is to enable people living with MS and NMOSD to maintain life to the fullest. With over 250,000 people treated with OCREVUS, we continue to see significant reductions in MS disease progression balanced with favourable safety,” mentioned Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We are also focused on remaining unmet needs – such as earlier diagnosis and treatment – which is critical to ensure patients are receiving the most appropriate treatment.”

Multiple sclerosis (MS)
Roche will present 29 MS abstracts, together with data from a two-year interim evaluation of treatment-naive, early-stage sufferers with RRMS from the open label Phase IIIb ENSEMBLE research that may present the constructive affect on illness exercise and development when newly recognized sufferers are handled with OCREVUS, and outcomes from the biggest cumulative being pregnant dataset for an anti-CD20 MS medication in greater than 2,000 ladies handled with OCREVUS. Long-term data from all OCREVUS scientific trials in relapsing MS (RMS) and first progressive MS (PPMS) over 9 years will reinforce the persistently beneficial benefit-risk profile of OCREVUS.

Neuromyelitis optica spectrum dysfunction (NMOSD)
Roche will present 5 NMOSD abstracts, together with the event and testing of a healthcare claims-based algorithm to determine folks residing with NMOSD. Misdiagnosis of NMOSD is widespread and related to a delay in initiating upkeep remedy. This was highlighted in a research wanting to develop a clearer understanding of affected person traits, relapse severity and different drivers of remedy selection.

The growth of validated consensus statements on AQP4-IgG seropositive NMOSD administration will even be introduced with a deal with remedy suggestions together with satralizumab; these statements intention to optimise affected person outcomes via knowledgeable remedy choice making. The characterisation of illness severity and stability in NMOSD will even be introduced, with the intention of integrating these in worldwide NMOSD scientific follow.

Roche will even present the research design from a Phase III research that may consider the efficacy and security of satralizumab in MOGAD.

Follow Roche on Twitter by way of @Roche and sustain to date with ECTRIMS 2022 information and updates by utilizing the hashtag #ECTRIMS2022.

About OCREVUS (ocrelizumab)
OCREVUS is the primary and solely remedy accepted for each RMS (together with RRMS and lively, or relapsing, secondary progressive MS [SPMS], in addition to clinically remoted syndrome [CIS] in the U.S.) and PPMS. OCREVUS is a humanised monoclonal antibody designed to goal CD20-positive B cells, a selected sort of immune cell thought to be a key contributor to myelin (nerve cell insulation and help) and axonal (nerve cell) injury. This nerve cell injury can lead to incapacity in folks with MS. Based on preclinical research, OCREVUS binds to CD20 cell floor proteins expressed on sure B cells, however not on stem cells or plasma cells, suggesting that necessary features of the immune system could also be preserved. OCREVUS is run by intravenous infusion each six months. The preliminary dose is given as two 300 mg infusions given two weeks aside. Subsequent doses are given as single 600 mg infusions. 

About ENSPRYNG (satralizumab)
ENSPRYNG, which was designed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that targets interleukin-6 (IL-6) receptor exercise. ENSPRYNG was designed utilizing novel recycling antibody expertise which, in contrast to standard expertise, permits for longer period of the antibody and subcutaneous dosing each 4 weeks.

Positive Phase III outcomes for ENSPRYNG, as each monotherapy and in mixture with baseline immunosuppressive remedy, display that IL-6 inhibition is an efficient therapeutic method for neuromyelitis optica spectrum dysfunction (NMOSD). ENSPRYNG is presently accepted for NMOSD in 72 international locations with additional functions below evaluate with quite a few regulators. Roche continues to examine ENSPRYNG in additional indications together with generalised myasthenia gravis (gMG), Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) and Autoimmune Encephalitis (AIE).

ENSPRYNG was granted Breakthrough Therapy Designation for the remedy of NMOSD by the FDA in December 2018 and designated as an orphan drug for NMOSD in the United States, Europe, Russia and Japan.

In addition, it has been designated as an orphan drug for gMG, MOGAD and AIE (NMDAR).

About Roche in neuroscience
Neuroscience is a serious focus of analysis and growth at Roche. Our objective is to pursue ground-breaking science to develop new remedies that assist enhance the lives of individuals with persistent and probably devastating illnesses.

Roche has each accepted and investigational medicines throughout multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum dysfunction, myasthenia gravis, Alzheimer’s illness, Huntington’s illness, Parkinson’s illness and Duchenne muscular dystrophy. Together with our companions, we’re dedicated to pushing the boundaries of scientific understanding to clear up among the most tough challenges in neuroscience at present.

About Roche
Founded in 1896 in Basel, Switzerland, as one of many first industrial producers of branded medicines, Roche has grown into the world’s largest biotechnology firm and the worldwide chief in in-vitro diagnostics. The firm pursues scientific excellence to uncover and develop medicines and diagnostics for bettering and saving the lives of individuals all over the world. We are a pioneer in personalised healthcare and need to additional rework how healthcare is delivered to have a good larger affect. To present the most effective look after every individual we associate with many stakeholders and mix our strengths in Diagnostics and Pharma with data insights from the scientific follow.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the sustainable firms in the prescription drugs trade by the Dow Jones Sustainability Indices for the thirteenth consecutive 12 months. This distinction additionally displays our efforts to enhance entry to healthcare along with native companions in each nation we work.

Genentech, in the United States, is an entirely owned member of the Roche Group. Roche is almost all shareholder in Chugai Pharmaceutical, Japan.

For extra info, please go to www.roche.com.

All emblems used or talked about in this launch are protected by regulation.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected]

Roche Investor Relations

Investor Relations North America

• 19102022_MR_ocrevusECTRIMS_en